New infusion significantly boosts cash position for Tewksbury, Mass., diagnosticis firm; three board members and one existing shareholder join new institutional investor in stock purchase
Cambridge Heart Inc. (OTC:CAMH) has $1.85 million in new funding, likely doubling its cash position in short order through a private placement of convertible preferred stock with a group of largely unidentified investors.
The deal, announced Monday by the Tewksbury, Mass.-based company, offered up 1,852 shares of Series D convertible preferred stock priced at $1,000 per share. Each preferred share can be converted into 12,195 shares of common stock — equal to 8.2 cents per common share, a 15-percent premium over the stock's average price in recent weeks.
Hologic wins FDA approval for its new C-View 2D imaging software for use with its 3D breast...
The hallowed emerging markets in Brazil, Russia, India and China aren't generating the kind of growth...
Medical device company Bausch + Lomb won FDA approval for its Trulign Toric intraocular lens, the 1st...
California medical device maker Claret Medical's embolic protection technology captures debris...
Texas-based Galt Medical Corp. is reportedly laying off 139 workers as it shutters its hometown plant...